Le Lézard
Classified in: Health

PA5051 Shows 3-Fold Decrease In Body Fat And 5-Fold Increase In IL-6 Confirming Its Support For Weight Management

FAIRFIELD, N.J., July 17, 2019 /PRNewswire-PRWeb/ -- A new pilot study recently published in CDN (Current Developments In Nutrition) concluded that Pediococcus acidilactici NRRL B-50517 (PA-5051) is a safe probiotic for human consumption and may be useful in reducing body fat and pro-inflammatory markers. The study is entitled "Pediococcus Acidilactici NRRL B-50517 as a Safe Probiotic for Regulation of Weight-Related Pro-inflammatory Cytokines: A Double-blind Placebo-controlled Pilot Study (P21-026-19)."

Prepared by Dr. Jhy Jhu Lin, Imagilin Technology, LLC; Dr. Jeanne O'Connell, Restorasis Health at Sylvana Institute; and Dr. Steve Sinclair, Healing Power of Nature, the study was conducted over a three-month period. The goal was to determine the effectiveness of the probiotic PA-5051 in resisting high temperatures (up to 85°C), stomach acids and the air. Clinical evaluation of the effectiveness of PA-5051 as a safe probiotic for the regulation of weight-related health issues was also observed. 30 healthy participants were randomly assigned two capsules of placebo or PA-5051 (4 billion CFU) to be taken daily for three months. In order to ensure proper daily dosage administration and to collect the results of a questionnaire relating to 6 categories of gut functions for safety evaluation, bi-weekly phone interviews were conducted. Both percent of body fat and serum preparation for cytokine analysis were performed at the beginning and the end of clinic study.

No statistical differences between the control group and PA-5051 treated group was observed from all 6 categories of gut functions- appetite, energy, bowel movement, stool quality, bloating and gas through the three months study. This demonstrates that PA-5051 is a safe probiotic for human consumption. Interestingly, after taken three months with PA-5051 probiotics, the PA-5051 treated group showed a 3 fold decrease in the percent of body fat, 5 fold decrease in cytokine IL-6 and 2.6 fold decrease in cytokine IL-23 comparing those of control group. This indicates that PA-5051 may be applied for body weight management.

Link to review: https://dx.doi.org/10.1093%2Fcdn%2Fnzz041.P21-026-19


SOURCE A&B Ingredients

These press releases may also interest you

at 23:49
Nurish.Me Inc. (Subsidiary - F/K/A Altavoz Entertainment, Inc.; OTC Pink: AVOZ) (the "Company"), an emerging leader in the dietary supplement industry for delivering clinically proven solutions for brain and immune system support, announces the...

at 21:29
Original Notice Why you should take note The Public Health Agency of Canada (PHAC) is collaborating with provincial public health partners, the Canadian Food Inspection Agency (CFIA) and Health Canada to investigate an outbreak of E. coli infections...

at 19:23
The organizers of Tremblant's 24h are elated to announce the unprecedented success of their 19th edition. The event culminated in a record fundraising total of $4,789,709 in support of children's causes, nearly $700,000 more than last year. This...

at 19:10
The Canadian Food Inspection Agency (CFIA) is warning consumers not to consume the recalled product described below. This product is not likely to be available at retail stores, but may still be in consumer's homes. The following product has been...

at 18:05
Rocket Pharmaceuticals, Inc. ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces encouraging preliminary results from its Phase 1 trial of...

at 17:45
Aurora Bio, Inc www.Aurorabioinc.com today announced data for the company's novel PET radiotracer, AUR01, in development for systemic amyloidosis, was presented by Dr. Jonathan Wall, at ASH2019, in Orlando, FL. Spencer Guthrie, Chief Executive...

News published on 17 july 2019 at 14:00 and distributed by: